TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial
Brief Summary: The objective of this Randomised Controlled Trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP) including STRIP assistant (STRIPA) implemented by an appropriately qualified team will lead to an improvement in clinical and economic outcomes among patients aged 70 years and more with multimorbidity and polypharmacy.


Options:
A: Arm Label: Pharmacist service,; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist service; Assigned to Arm(s): Pharmacist service,
B: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
C: Arm Label: STRIP intervention; Type: EXPERIMENTAL; Interventions: Other: STRIP intervention | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: STRIP intervention; Assigned to Arm(s): STRIP intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Other: tele-expertise | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: tele-expertise; Assigned to Arm(s): experimental group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial
Brief Summary: The objective of this Randomised Controlled Trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP) including STRIP assistant (STRIPA) implemented by an appropriately qualified team will lead to an improvement in clinical and economic outcomes among patients aged 70 years and more with multimorbidity and polypharmacy.


Options:
A: Arm Label: STRIP intervention; Type: EXPERIMENTAL; Interventions: Other: STRIP intervention | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: STRIP intervention; Assigned to Arm(s): STRIP intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient Navigator, Other: Usual care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient Navigator; Assigned to Arm(s): Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Navigator
C: Arm Label: Comprehensive Geriatric Assessment; Type: EXPERIMENTAL; Interventions: Other: Comprehensive Geriatric Assessment | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive Geriatric Assessment; Assigned to Arm(s): Comprehensive Geriatric Assessment
D: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia
Brief Summary: The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).


Options:
A: Arm Label: Participants receiving Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Participants receiving Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Participants receiving Daprodustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Participants receiving Epoetin alfa
B: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat tablets, Drug: Saline vials or bags | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Matching placebo tablets, Drug: Epoetin alfa vials | Intervention Type: DRUG; Name: Daprodustat tablets; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Matching placebo tablets; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa vials; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Saline vials or bags; Assigned to Arm(s): Daprodustat
C: Arm Label: AKB-6548 240 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 370 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 500 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: AKB-6548 630 mg; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 240 mg, AKB-6548 370 mg, AKB-6548 500 mg, AKB-6548 630 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: rHuEPO or DA to ASP1517; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: rHuEPO or DA to DA; Type: EXPERIMENTAL; Interventions: Drug: DA | Arm Label: Epoetin beta pegol to ASP1517; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): Epoetin beta pegol to ASP1517, rHuEPO or DA to ASP1517 | Intervention Type: DRUG; Name: DA; Assigned to Arm(s): rHuEPO or DA to DA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Health in Patients With Primary Hyperparathyroidism: Effect of Parathyroidectomy on Cardiovascular Health: A Randomized Controlled Trial
Brief Summary: The aim of this study is to establish whether patients with mild primary hyperparathyroidism (PHPT) have an increased risk of cardiovascular diseases. The primary outcome is to determine whether arterial stiffness and blood pressure will decrease in patients with mild PHPT 3-month after parathyroidectomy (PTX).


Options:
A: N/A
B: Arm Label: Early parathyroidectomy group; Type: EXPERIMENTAL; Interventions: Procedure: Early parathyroidectomy group (EPTX-group) | Arm Label: Late parathyroidectomy group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Early parathyroidectomy group (EPTX-group); Assigned to Arm(s): Early parathyroidectomy group
C: Arm Label: Parathyroidectomy + Observation; Type: EXPERIMENTAL; Interventions: Procedure: Parathyroid Surgery, Behavioral: Telephone Interview, Behavioral: Polysomnography (PSG) | Arm Label: Observation Alone; Type: OTHER; Interventions: Behavioral: Telephone Interview, Procedure: Parathyroid Surgery, Behavioral: Polysomnography (PSG) | Intervention Type: PROCEDURE; Name: Parathyroid Surgery; Assigned to Arm(s): Parathyroidectomy + Observation | Intervention Type: BEHAVIORAL; Name: Telephone Interview; Assigned to Arm(s): Observation Alone, Parathyroidectomy + Observation | Intervention Type: PROCEDURE; Name: Parathyroid Surgery; Assigned to Arm(s): Observation Alone | Intervention Type: BEHAVIORAL; Name: Polysomnography (PSG); Assigned to Arm(s): Observation Alone, Parathyroidectomy + Observation
D: Arm Label: Cinacalcet; Type: EXPERIMENTAL; Interventions: Drug: Cinacalcet, Procedure: parathyroid adenomectomy | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: PROCEDURE; Name: parathyroid adenomectomy; Assigned to Arm(s): Cinacalcet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Heightened Levels of Aggression in Traumatized Offenders With Psychotherapeutic Means: A Randomized Controlled Trial in Eastern DR Congo
Brief Summary: Heightened levels of aggression are fuelling violent incidents at all levels, especially in post-war regions. Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) aims to address trauma symptoms along with reactive and instrumental/appetitive aggression to encounter the downward cycle of perpetration and enforce a sustainable (re-)integration into civil life. In the present study, the investigators provide an adapted version of FORNET to former combatants in the North Kivu, Eastern DR Congo. Structured baseline, 3 and 6 month follow up interviews will be administered to assess the main outcome measures recent violent acts and appetitive aggression.


Options:
A: Arm Label: problem solving therapy + Behavioral Treatment of Insomnia; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving therapy and Brief Behavioral Treatment of Insomnia | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Problem Solving therapy and Brief Behavioral Treatment of Insomnia; Assigned to Arm(s): problem solving therapy + Behavioral Treatment of Insomnia
B: Arm Label: Narrative Exposure Therapy (FORNET, adapted version); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: FORNET (adapted version) | Arm Label: Waitlist control or treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: FORNET (adapted version); Assigned to Arm(s): Narrative Exposure Therapy (FORNET, adapted version)
C: Arm Label: Obese patients treated with bariatric surgery; Type: EXPERIMENTAL; Interventions: Procedure: Bariatric surgery | Arm Label: Obese patients not treated with bariatric surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Obese patients treated with bariatric surgery
D: Arm Label: Immediate; Type: EXPERIMENTAL; Interventions: Behavioral: eHealth for Covid-19 prevention and support | Arm Label: Waitlist; Type: OTHER; Interventions: Behavioral: eHealth for Covid-19 prevention and support | Intervention Type: BEHAVIORAL; Name: eHealth for Covid-19 prevention and support; Assigned to Arm(s): Immediate, Waitlist

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Heightened Levels of Aggression in Traumatized Offenders With Psychotherapeutic Means: A Randomized Controlled Trial in Eastern DR Congo
Brief Summary: Heightened levels of aggression are fuelling violent incidents at all levels, especially in post-war regions. Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) aims to address trauma symptoms along with reactive and instrumental/appetitive aggression to encounter the downward cycle of perpetration and enforce a sustainable (re-)integration into civil life. In the present study, the investigators provide an adapted version of FORNET to former combatants in the North Kivu, Eastern DR Congo. Structured baseline, 3 and 6 month follow up interviews will be administered to assess the main outcome measures recent violent acts and appetitive aggression.


Options:
A: Arm Label: Emotion Regulation Group Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Skills training of Affect-Regulation - A culture-sensitive approach: STARK | Arm Label: Wait List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Skills training of Affect-Regulation - A culture-sensitive approach: STARK; Assigned to Arm(s): Emotion Regulation Group Therapy
B: Arm Label: Narrative Exposure Therapy (FORNET, adapted version); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: FORNET (adapted version) | Arm Label: Waitlist control or treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: FORNET (adapted version); Assigned to Arm(s): Narrative Exposure Therapy (FORNET, adapted version)
C: Arm Label: Family intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family intervention | Arm Label: Waitlist control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family intervention; Assigned to Arm(s): Family intervention
D: Arm Label: Wait List Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma Focused Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Trauma Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Intervention Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Tranexamic Acid (TXA) in Hip Fractures, A Double-Blind, Randomized Controlled Trial
Brief Summary: Mechanisms by which to reduce exposure to allogeneic blood are of financial and clinical benefit in the hip fracture population. Tranexamic acid (TXA) is an inexpensive medication with low complication risk. Its use in the hip fracture population is unproven. The purpose of this study is to evaluate the efficacy and safety of topical tranexamic acid in reduction of peri-operative blood loss in hip fracture surgery.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid (Exacyl) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic acid (Exacyl); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: TXA + IIM; Type: EXPERIMENTAL; Interventions: Drug: Iron Isomaltoside 1000, Drug: Tranexamic Acid | Arm Label: Placebo TXA + IIM; Type: EXPERIMENTAL; Interventions: Drug: Iron Isomaltoside 1000, Drug: Placebos tranexamic acid | Arm Label: TXA + Placebo IIM; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Placebos iron isomaltoside 1000 | Arm Label: Placebo TXA + Placebo IIM; Type: EXPERIMENTAL; Interventions: Drug: Placebos iron isomaltoside 1000, Drug: Placebos tranexamic acid | Intervention Type: DRUG; Name: Iron Isomaltoside 1000; Assigned to Arm(s): Placebo TXA + IIM, TXA + IIM | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA + IIM, TXA + Placebo IIM | Intervention Type: DRUG; Name: Placebos iron isomaltoside 1000; Assigned to Arm(s): Placebo TXA + Placebo IIM, TXA + Placebo IIM | Intervention Type: DRUG; Name: Placebos tranexamic acid; Assigned to Arm(s): Placebo TXA + IIM, Placebo TXA + Placebo IIM
C: Arm Label: Tranexamic Acid Wash; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Saline Wash; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline Wash | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid Wash | Intervention Type: OTHER; Name: Saline Wash; Assigned to Arm(s): Saline Wash
D: Arm Label: Adrenaline; Type: EXPERIMENTAL; Interventions: Drug: Adrenaline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: iTRACC (Improving Technology-Assisted Recording of Asthma Control in Children)
Brief Summary: The goal of this study is to determine whether a sensor-enabled, clinically integrated, mobile health asthma program can improve asthma outcomes among 4-17 year old children with moderate-to-severe asthma.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Remote Health Management Sensor Platform | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Remote Health Management Sensor Platform; Assigned to Arm(s): Intervention
B: Arm Label: Case Group; Type: N/A; Interventions: N/A | Arm Label: Control Group; Type: N/A; Interventions: Other: MyMediHealth access | Intervention Type: OTHER; Name: MyMediHealth access; Assigned to Arm(s): Control Group
C: Arm Label: Tailored asthma management program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored asthma management program | Arm Label: Generic web-based education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based education | Intervention Type: BEHAVIORAL; Name: Tailored asthma management program; Assigned to Arm(s): Tailored asthma management program | Intervention Type: BEHAVIORAL; Name: Generic web-based education; Assigned to Arm(s): Generic web-based education
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: Spencer | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spencer; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of a Robotic Exoskeleton to Promote Walking Recovery After Stroke - Phase 2
Brief Summary: To determine the effect of using a robotic exoskeleton to allow walking practice after stroke, compared to usual physiotherapy care, on recovery of walking ability and secondary outcomes.


Options:
A: Arm Label: Robot, then conventional training; Type: EXPERIMENTAL; Interventions: Other: Robot, then conventional training | Arm Label: Conventional, then robot training; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional, then robot training | Intervention Type: OTHER; Name: Robot, then conventional training; Assigned to Arm(s): Robot, then conventional training | Intervention Type: OTHER; Name: Conventional, then robot training; Assigned to Arm(s): Conventional, then robot training
B: Arm Label: Stride Management Assist (SMA) System; Type: EXPERIMENTAL; Interventions: Device: The Stride Management Assist (SMA) System | Arm Label: Impairment based therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Impairment based therapy | Intervention Type: DEVICE; Name: The Stride Management Assist (SMA) System; Assigned to Arm(s): Stride Management Assist (SMA) System | Intervention Type: OTHER; Name: Impairment based therapy; Assigned to Arm(s): Impairment based therapy
C: Arm Label: Samsung Hip Assist v1; Type: EXPERIMENTAL; Interventions: Device: gait rehabilitation with Samsung Hip Assist v1 | Arm Label: Conventional gait training; Type: ACTIVE_COMPARATOR; Interventions: Other: gait rehabilitation without Samsung Hip Assist v1 | Intervention Type: DEVICE; Name: gait rehabilitation with Samsung Hip Assist v1; Assigned to Arm(s): Samsung Hip Assist v1 | Intervention Type: OTHER; Name: gait rehabilitation without Samsung Hip Assist v1; Assigned to Arm(s): Conventional gait training
D: Arm Label: Exoskeleton Program; Type: EXPERIMENTAL; Interventions: Device: Exoskeleton Program | Arm Label: Usual Care Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Program | Intervention Type: DEVICE; Name: Exoskeleton Program; Assigned to Arm(s): Exoskeleton Program | Intervention Type: OTHER; Name: Usual Care Program; Assigned to Arm(s): Usual Care Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Danish Rct on Exercise Versus Arthroscopic Meniscal Surgery for Young Adults (DREAM) - A Randomized Controlled Trial of Meniscal Tear Treatment in Young Adults
Brief Summary: There are two cartilage structures in each knee joint called a meniscus. A torn meniscus can be caused by either a smaller or larger trauma or be a degenerative age-related tear. Arthroscopic meniscal surgery is the most common orthopedic procedure, but no high-quality studies have investigated the efficacy of meniscal surgery for younger patients (i.e. 40 years or younger) in comparison to non-surgical treatments.

The purpose of this study is to determine if a strategy of early arthroscopic meniscal surgery (repair or resection) is superior to a strategy of initial individualized supervised exercise therapy including patient education with the option of later surgery if needed in improving pain, function and quality of life in young patients (18-40 years) with meniscal tears.

The hypothesis is that patients treated with early arthroscopic meniscal surgery will improve more than patients treated with exercise and education.


Options:
A: Arm Label: Arthroscopic partial meniscectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic partial meniscectomy | Arm Label: Arthroscopy (diagnostic); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopy (diagnostic) | Intervention Type: PROCEDURE; Name: Arthroscopic partial meniscectomy; Assigned to Arm(s): Arthroscopic partial meniscectomy | Intervention Type: PROCEDURE; Name: Arthroscopy (diagnostic); Assigned to Arm(s): Arthroscopy (diagnostic)
B: Arm Label: Arthroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic meniscal repair or resection | Arm Label: Exercise and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and education | Intervention Type: PROCEDURE; Name: Arthroscopic meniscal repair or resection; Assigned to Arm(s): Arthroscopy | Intervention Type: BEHAVIORAL; Name: Exercise and education; Assigned to Arm(s): Exercise and Education
C: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management
D: Arm Label: Arthroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Knee arthroscopy | Arm Label: Exercise therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Knee arthroscopy; Assigned to Arm(s): Arthroscopy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Phase II Clinical Trials of Thalidomide in NTDT
Brief Summary: This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of NTDT to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion.15\~30 patients will be enrolled, including type α 5\~13 cases, type β 10\~17 cases.


Options:
A: Arm Label: research; Type: N/A; Interventions: Drug: Yisuishengxue Granule | Arm Label: clinical research; Type: N/A; Interventions: Drug: Yisuishengxue Granule | Intervention Type: DRUG; Name: Yisuishengxue Granule; Assigned to Arm(s): clinical research, research
B: Arm Label: Hydroxyurea,blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydroxyurea, blood transfusion | Arm Label: Hydroxyurea, Epiao; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea ,Epiao | Intervention Type: DRUG; Name: Hydroxyurea ,Epiao; Assigned to Arm(s): Hydroxyurea, Epiao | Intervention Type: DRUG; Name: hydroxyurea, blood transfusion; Assigned to Arm(s): Hydroxyurea,blood transfusion
C: Arm Label: thalidomide thalassemia; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): thalidomide thalassemia
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Drug: Colla corii asini | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Colla corii asini; Assigned to Arm(s): Intervention group

Answer: C